KRAS and colorectal carcinoma: KRAS mutated CRC patients are known to be resistant to standard epidermal growth factor receptor (EGFR) inhibitory treatments.22,23 The output of our analysis can thus give some indications concerning possible new processes to be targeted in KRAS-mutated patients.